229 related articles for article (PubMed ID: 33875521)
1. Select Antitumor Cytotoxic CD8
Baptista MJ; Baskar S; Gaglione EM; Keyvanfar K; Ahn IE; Wiestner A; Sun C
Clin Cancer Res; 2021 Aug; 27(16):4624-4633. PubMed ID: 33875521
[TBL] [Abstract][Full Text] [Related]
2. BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL.
Mhibik M; Gaglione EM; Eik D; Kendall EK; Blackburn A; Keyvanfar K; Baptista MJ; Ahn IE; Sun C; Qi J; Rader C; Wiestner A
Blood; 2021 Nov; 138(19):1843-1854. PubMed ID: 34046681
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
[TBL] [Abstract][Full Text] [Related]
4. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
5. Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice.
Hanna BS; Yazdanparast H; Demerdash Y; Roessner PM; Schulz R; Lichter P; Stilgenbauer S; Seiffert M
Haematologica; 2021 Apr; 106(4):968-977. PubMed ID: 32139435
[TBL] [Abstract][Full Text] [Related]
6. Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.
Yin Q; Sivina M; Robins H; Yusko E; Vignali M; O'Brien S; Keating MJ; Ferrajoli A; Estrov Z; Jain N; Wierda WG; Burger JA
J Immunol; 2017 Feb; 198(4):1740-1747. PubMed ID: 28077600
[TBL] [Abstract][Full Text] [Related]
7. A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
Robinson HR; Qi J; Cook EM; Nichols C; Dadashian EL; Underbayev C; Herman SEM; Saba NS; Keyvanfar K; Sun C; Ahn IE; Baskar S; Rader C; Wiestner A
Blood; 2018 Aug; 132(5):521-532. PubMed ID: 29743179
[TBL] [Abstract][Full Text] [Related]
8. Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia.
Rezvany MR; Jeddi-Tehrani M; Wigzell H; Osterborg A; Mellstedt H
Blood; 2003 Feb; 101(3):1063-70. PubMed ID: 12393705
[TBL] [Abstract][Full Text] [Related]
9. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
[TBL] [Abstract][Full Text] [Related]
10. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia.
Scrivener S; Goddard RV; Kaminski ER; Prentice AG
Leuk Lymphoma; 2003 Mar; 44(3):383-9. PubMed ID: 12688308
[TBL] [Abstract][Full Text] [Related]
11. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure.
Gauthier J; Hirayama AV; Purushe J; Hay KA; Lymp J; Li DH; Yeung CCS; Sheih A; Pender BS; Hawkins RM; Vakil A; Phi TD; Steinmetz RN; Shadman M; Riddell SR; Maloney DG; Turtle CJ
Blood; 2020 May; 135(19):1650-1660. PubMed ID: 32076701
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic CD4+ T cells in patients with B cell chronic lymphocytic leukemia kill via a perforin-mediated pathway.
Porakishvili N; Kardava L; Jewell AP; Yong K; Glennie MJ; Akbar A; Lydyard PM
Haematologica; 2004 Apr; 89(4):435-43. PubMed ID: 15075077
[TBL] [Abstract][Full Text] [Related]
13. Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells.
Xia M; Luo TY; Shi Y; Wang G; Tsui H; Harari D; Spaner DE
J Immunol; 2020 Nov; 205(10):2629-2639. PubMed ID: 33067379
[TBL] [Abstract][Full Text] [Related]
14. Lymphocyte migration and retention properties affected by ibrutinib in chronic lymphocytic leukemia.
Rey-Barroso J; Munaretto A; Rouquié N; Mougel A; Chassan M; Gadat S; Dewingle O; Poincloux R; Cadot S; Ysebaert L; Quillet-Mary A; Dupré L
Haematologica; 2024 Mar; 109(3):809-823. PubMed ID: 37381758
[TBL] [Abstract][Full Text] [Related]
15. Abundant cytomegalovirus (CMV) reactive clonotypes in the CD8(+) T cell receptor alpha repertoire following allogeneic transplantation.
Link CS; Eugster A; Heidenreich F; Rücker-Braun E; Schmiedgen M; Oelschlägel U; Kühn D; Dietz S; Fuchs Y; Dahl A; Domingues AM; Klesse C; Schmitz M; Ehninger G; Bornhäuser M; Schetelig J; Bonifacio E
Clin Exp Immunol; 2016 Jun; 184(3):389-402. PubMed ID: 26800118
[TBL] [Abstract][Full Text] [Related]
16. CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells.
Martens AWJ; Janssen SR; Derks IAM; Adams Iii HC; Izhak L; van Kampen R; Tonino SH; Eldering E; van der Windt GJW; Kater AP
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581054
[TBL] [Abstract][Full Text] [Related]
17. Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.
Molica S; Gianfelici V; Levato L
Expert Opin Emerg Drugs; 2020 Mar; 25(1):25-35. PubMed ID: 31996046
[No Abstract] [Full Text] [Related]
18. T Cell Receptor Diversity and Lineage Relationship between Virus-Specific CD8 T Cell Subsets during Chronic Lymphocytic Choriomeningitis Virus Infection.
Chang YM; Wieland A; Li ZR; Im SJ; McGuire DJ; Kissick HT; Antia R; Ahmed R
J Virol; 2020 Sep; 94(20):. PubMed ID: 32759317
[TBL] [Abstract][Full Text] [Related]
19. BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia.
Fiorcari S; Maffei R; Vallerini D; Scarfò L; Barozzi P; Maccaferri M; Potenza L; Ghia P; Luppi M; Marasca R
Front Immunol; 2020; 11():2158. PubMed ID: 32983178
[TBL] [Abstract][Full Text] [Related]
20. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY
Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]